Medplus Health Services Limited has announced the release of pledged shares by its promoter entity Agilemed Investments Private Limited following successful debt repayment. The company filed the regulatory disclosure under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 31, marking the completion of its debt refinancing initiative.

Share Pledge Release Details

Agilemed Investments Private Limited released 41,71,970 equity shares from pledge arrangements on December 24. The release was executed following repayment of existing debt obligations to multiple lenders including Catalyst Trusteeship Limited and Modulus Alternatives Investment Managers Limited.

Updated Promoter Shareholding Structure

Following the pledge release, the promoter group's encumbrance profile has been significantly reduced. The total promoter shareholding remains stable at 40.29% while the pledged portion has decreased substantially.

Debt Refinancing Framework

The share pledge release represents the successful completion of the debt refinancing framework involving non-convertible debentures. The arrangement included multiple financial instruments with structured repayment mechanisms to debenture trustees and lenders.

Regulatory Compliance and Impact

The company has fulfilled all disclosure requirements under SEBI regulations with comprehensive documentation filed on December 31, 2025. The encumbrance release demonstrates improved financial flexibility at the promoter level while maintaining strategic control over the healthcare retail chain.

The successful debt repayment and consequent pledge release reflects the company's strengthened financial position. This development provides enhanced operational flexibility to the promoter group while reducing overall leverage in the shareholding structure of Medplus Health Services Limited.

Medplus Health Services Limited has informed stock exchanges about regulatory action taken against its subsidiary, involving the suspension of drug licenses for multiple store locations in Maharashtra.

Subsidiary Faces License Suspension Orders

Optival Health Solutions Private Limited, a subsidiary of Medplus Health Services, has received three suspension orders for drug licenses affecting stores in Maharashtra. The orders were received on December 13, 2025, from the Assistant Commissioner Licensing Authority, Food Drug Administration, Maharashtra.

The suspensions target stores located in Amravati and Nagpur districts, with each suspension lasting five days. The regulatory action has been taken under Rule 65 of the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945.

Financial Impact Assessment

The company has quantified the potential revenue impact from these license suspensions across the affected locations:

The total potential revenue loss across the affected locations is estimated at ₹10.17 lakhs.

Regulatory Compliance and Disclosure

The disclosure has been made pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, read with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024. These regulations require listed entities to disclose material events affecting their operations or subsidiaries.

The company has stated that detailed information regarding this matter will be available on its official website at www.medplusindia.com , as well as on the websites of BSE Limited and National Stock Exchange of India Limited. This ensures transparency and accessibility of information for all stakeholders and regulatory compliance requirements.